World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care Committee
Abstract
Ideas and Opinions18 September 2018World Health Organization Guidelines on Medicines for Diabetes Treatment Intensification: Commentary From the American College of Physicians High Value Care CommitteeLinda L. Humphrey, MD, MPH, Devan Kansagara, MD, MCR, and Amir Qaseem, MD, PhD, MHA, for the High Value Care Committee of the American College of Physicians*Linda L. Humphrey, MD, MPHOregon Health & Science University, Portland, Oregon (L.L.H.), Devan Kansagara, MD, MCROregon Health & Science University and Veterans Affairs Medical Center, Portland, Oregon (D.K.), and Amir Qaseem, MD, PhD, MHAAmerican College of Physicians, Philadelphia, Pennsylvania (A.Q.), for the High Value Care Committee of the American College of Physicians*Author, Article, and Disclosure Informationhttps://doi.org/10.7326/M18-1148 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail More than 400 million adults worldwide are living with diabetes, and the World Health Organization (WHO) should be commended for its leadership in combating the global epidemic. The recent WHO guideline on managing diabetes mellitus contains important considerations, including evidence about benefits and harms of medications, intervention costs, and application to resource-poor settings (1, 2). The guideline reinforces several others—including the American College of Physicians (ACP) guideline (3)—and highlights the importance of lifestyle changes…
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.